Incyte stock plummets following disappointing clinical study results
Incyte Corp. ’s stock price plunged nearly 20 percent Friday after the Wilmington biotechnology company announced disappointing late-stage study results for an experimental cancer therapy.
The results from a phase-III clinical study, testing Incyte’s new drug candidate epacadostat with Merck& Co. Inc. ’s immunotherapy drug Keytruda, found the combination therapy did not improve progression-free survival in patients with metastatic melanoma, a type of skin cancer.
Incyte and Merck said, at…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: John George Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Immunotherapy | Melanoma | Merck | Skin | Skin Cancer | Study